Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Open Access
- 15 October 2012
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 41 (6) , 2109-2118
Abstract
Mesothelin is expressed in various types of malignant tumors, and we recently reported that the expression of mesothelin was related to unfavorable patient outcome in pancreatic ductal adenocarcinoma and gastric adenocarcinoma. In this study, we examined the clinicopathological significance of mesothelin expression in extrahepatic bile duct cancer (EHBDCA), especially in terms of its association with the staining pattern. Tissue samples from 61 EHBDCA (16 hilar cholangiocarcinoma, 17 upper bile duct adenocarcinoma, 20 middle bile duct adenocarcinoma and 8 distal bile duct adenocarcinoma) were immunohistochemically examined. The expression levels of mesothelin in tumor cells was classified into the localization of mesothelin in luminal membrane and/or cytoplasm, in addition to high and low according to the staining intensity and proportion as a conventional analysis. 'High-level expression' of mesothelin (47.5%) was statistically correlated with liver metastasis (P=0.013) and poorer patient outcome (P=0.022), while 'luminal' membrane positive' of mesothelin (52.5%) was more significantly correlated with liver metastasis (P=0.006), peritoneal metastasis (P=0.024) and unfavorable patient outcome (P=0.017). Moreover, we found that 'cytoplasmic expression' isolated from 'luminal membrane negative' of mesothelin represented the best patient prognosis throughout this study. We describe the expression pattern level of mesothelin, i.e., in luminal membrane or cytoplasm both high and low level, evidently indicate the patient prognosis of EH BDCA, suggesting the pivotal role of mesothelin in cancer promotion depending on its intracellular localization.Keywords
This publication has 36 references indexed in Scilit:
- Adequate Lymph Node Assessment for Extrahepatic Bile Duct AdenocarcinomaAnnals of Surgery, 2010
- Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinomaBiomedical Research, 2009
- Distal Biliary MalignancySurgical Clinics of North America, 2008
- Proximal Biliary MalignancySurgical Clinics of North America, 2008
- Localization of Mesothelin in Epithelial Ovarian CancerApplied Immunohistochemistry & Molecular Morphology, 2005
- Application of Mesothelin Immunostaining in Tumor DiagnosisAmerican Journal of Surgical Pathology, 2003
- Value of Mesothelin Immunostaining in the Diagnosis of MesotheliomaLaboratory Investigation, 2003
- Staging, Resectability, and Outcome in 225 Patients With Hilar CholangiocarcinomaAnnals of Surgery, 2001
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992